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Resistance of human T-CFUcs to activated
cyclophosphamide: A feature common with critical marrow
stem cells?
J.E. Byfield & P.M. Calabro-Jones
Division ofRadiation Biology, University ofCalifornia San Diego, California 92093, USA.
It has been known for over a decade that the
alkylating agent Cyclophosphamide (CY) has a
differential effect on the immune system, exerting
greater toxicity against B than T lymphocytes
(Poulet & Turk, 1972; Stockman et al., 1983; Turk
et al., 1972). CY selectively depletes the B-cell rich
peripheral splenic pulp and exerts a greater
inhibition of stimulation of B-cells by pokeweed
mitogen than T cells by phytohaemagglutinin
(PHA; Stockman et al., 1973). This differential
effect is found even at the earliest time of life; CY
given to newly hatched chicks leads to a severe
depression of antibody synthesis in adult chickens
while T cell functions are virtually unimpaired
(Lerman & Weidanz, 1970). Recent experiments
have indicated that part of these effects are due to
inhibition of T suppressor cell activity (Turk &
Poulter, 1982). The exact mechanism by which this
selectivity is exerted could not previously be studied
in vitro since CY requires activation in the liver
(Hill, 1975). We show here that the newly available
active form of CY, phosphoramide mustard (PM,
Fenselau et al., 1977) is virtually inert against
colony-forming T cells in tissue culture at levels
highly cytotoxic to other cells. Cultured human T
lymphoma cells retain a significant amount of this
resistance; recent work in other laboratories
suggests that the same is true for important human
marrow-repopulating stem cells (see below).
To determine the effect of PM on T lymphocytes
we used the quantitative colony assay technique
we developed for examining the proliferation-
dependency of cytotoxicity in vitro. In this assay
(Byfield & Calabro-Jones 1981) purified prepara-
tions of mononuclear cells from human blood are
treated with PHA and the number of colonies
(T-CFUCS, T cell colony-forming units in culture)
are subsequently counted. The addition of active
cytotoxic drugs inhibits this colony formation and
yields survival curves similar to those found with
permanently explanted lines (Byfield & Calabro-
Jones, 1981). In the experiments reported here we
studied the effect of PM exposure both prior to and
after the induction of proliferation by PHA, using
an identical protocol employed by us with other
alkylating agents (Byfield & Calabro-Jones, 1981).
We have previously shown that the sequence of
exposure to PHA and drug influences the shape of
the resultant survival curves, the effect being a
function of solubility characteristics of each agent
(Byfield & Calabro-Jones, 1981). The survival
curves for log phase WI-L2 cells (a malignant
human B cell line) and CEM cells (a human T
lymphoma line) exposed to PM were also obtained.
In vitro activity of the PM was confirmed using
HeLa cells cultured by our standard colony-
counting method (Byfield et al., 1981). (The PM
was kindly synthesized by Dr. R. Struck).
We found (Figure 1) that the population of
human T cells that form colonies in semi-solid
medium after PHA stimulation were virtually
unaffected by PM at concentrations that reduced
Hela cell survival by almost 3 logs. All other
malignant lines we have studied thus far, both
rodent and human (Byfield et al., 1981; Murnane et
al., 1980), were also quite sensitive to PM. Unlike
other alkylating agents (cf. Byfield & Calabro-
Jones, 1981), the time of exposure to PHA made
no difference (Figure 1). The colony-forming
human T cells were almost totally resistant to PM
whether or not they were actively proliferating at
the time of PM exposure.
The resistance to PM of some human T cells
carried over into a human malignant T cell line
(CEM cells) when compared to a B cell line (WI-L2
line, Figure 2). In this case resistance was relative
rather than almost absolute as in the case of the
normal human T CFUcs. However, at PM
concentrations likely to be encountered in vivo
during human lymphoma therapy with CY (about a
1.0MM peak, cf. Wagner et al., 1977, equal to the
lowest PM concentration studied here), this
difference is likely to be significant.
The level of resistance of the colony-forming T
cells is impressive and seems capable of explaining
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Figure 1 Effect of activated cyclophosphamide
(Phosphoramide mustard, PM) on the survival human
T cell in vitro colony forming units (T-CFUcs). The
cells were exposed to PM either before (resting, 0) or
after (cycling, 0) PHA exposure. Survival of HeLa
cells measured with same batch of PM, (-).
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Figure 2 Survival of malignant human B cells (WI-
L2) (0) or T cells (CEM) (0) after a 60min exposure
to various concentrations ofPhosphoramide mustard.
the results of much of the earlier in vivo data. Since
activated CY has been shown to substantially
inhibit normal B cell colony formation in vitro
(Winklestein, 1982), the degree of resistance seen
here for colony-forming T cells appears sufficient to
explain the histological manifestations of CY
treatment in vivo (Stockman et al., 1973; Turk &
Poulter, 1982). Presumably part of the functional
manifestations of CY treatment stem from the
greatly enhanced ratio of surviving T to B cells.
However, it has been shown by others that some
human T cell functions, including mitogenic
stimulation of DNA replication can be inhibited by
activated CY (Korbling et al., 1982). This suggests
that the T cells that form colonies in semi-solid
medium after PHA exposure are probably a unique
population of the overall mass of T cells (only a
small fraction of T cells form such in vitro
colonies). Thus the resistance of T cells to CY
killing seems not to be universal but rather limited
to a select T cell fraction. This differential toxicity
may well contribute to the various functional effects
seen in vivo.
Finally, we would note that recent experiments
on both rodent and human marrow stem cells have
also suggested a select and differential toxicity of
activated CY. Thus it was initially shown that in
vitro treatment of rat bone marrow with 4-hydro-
peroxycyclophosphamide (a synthetic metabolic
precursor of PM) led to elimination of leukaemic
cells without seriously impairing the capacity of the
treated marrow to repopulate marrow-depleted
animals (Sarkis et al., 1980). Similar effects were
then shown in humans where CFUC could be
totally depleted in culture by activated CY.
Nevertheless, patients receiving donor marrow pre-
treated with activated CY in vitro showed
essentially normal marrow recovery kinetics (Kaizer
et al., 1982). These data strongly suggest that true
pluripotential marrow stem cells share with the
PHA-dependent colony-forming lymphocyte subset
a great resistance to killing by activated CY.
Clinical data on granulocyte and platelet recovery
patterns in patients (with lung cancer) treated with
massive doses of CY have also indicated normal
marrow recovery kinetics (Smith et al., 1983).
Overall, these results by other investigators show
clearly that CY exerts a selective toxicity against
various marrow clonogenic cells, some pluripotent
stem cells apparently being spared while the semi-
committed or committed cells that form most of the
colonies in vitro are killed. The widespread use of
CY against many malignant conditions may
therefore be based on this selective sparing of the
most important renewal cells in the marrow, a form
of selective toxicity not hitherto recognized.
The mechanism of cellular resistance shown by
marrow stem cells and the subset of T cells studiedCYCLOPHOSPHAMIDE AND T CELLS 405
here is not as yet known but physical exclusion of
the drug from these cells seems likely. Alternatively,
the drug could be inactivated within the cells. We
have shown that activated CY induces molecular
(excision) repair of CY-induced damage and that
these repair processes can be aborted by methylated
xanthines (Byfield et al., 1981; Murnane et al.,
1980). However, repair-related resistance of the
magnitude found here has not previously been
reported and seems unlikely to us. Our previous
experiments showed that a significant relative
resistance to alkylating agents stems from the
degree to which cell penetration can be expected
(Byfield & Calabro-Jones, 1981). This is especially
true for drugs that are taken up by cellular
transport processes. In such cases the toxicity
exerted by each alkylating agent was a function of
the activity of those transport processes. (Byfield &
Calabro-Jones, 1981). We believe the most plausible
explanation of our results is that PM does not
enter the colony-forming T cells to a significant
degree; if correct it would presumably hold true for
pluripotent marrow stem cells as well. This suggests
that either the two cell types are close in the
cellular hierarchy ofhaematolymphogenous differen-
tiation and, as a consequence, share this drug
exclusion property or that exclusion (or in-
activation) of compounds like PM is a conferred
property of some resting stem cells. If this
explanation is correct then the synthesis of other
agents with useful differential effects based on pre-
defined cell-entry characteristics may be possible.
Our initial experiments had already suggested the
potential existence of anti-cancer agents with this
kind of selective toxicity (Byfield & Calabro-Jones).
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